Unlike other neovascular conditions such as wet AMD, where CT reduction serves as a marker of choroidal hyperpermeability improvement with anti-VEGF treatment, no significant CT changes were observed in our cohort, regardless of injection frequency. The gene discussed is VEGFA; the disease is wet macular degeneration.